Access cutting-edge triple negative breast cancer treatment through this clinical trial at a research site in Danvers. Study-provided care at no cost to qualified participants.
Access triple negative breast cancer specialists in Danvers at no cost
This study follows strict safety protocols and ethical guidelines
All study-related triple negative breast cancer treatment provided free
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Sponsor: Massachusetts General Hospital
Check if you qualify for this triple negative breast cancer clinical trial in Danvers, MA
If you're searching for triple negative breast cancer treatment options in Danvers, MA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Danvers research site is actively enrolling participants for this clinical trial. You'll receive care from experienced triple negative breast cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.